» Articles » PMID: 11055896

Distinct Missense Mutations of the FGFR3 Lys650 Codon Modulate Receptor Kinase Activation and the Severity of the Skeletal Dysplasia Phenotype

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 2000 Oct 31
PMID 11055896
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

The fibroblast growth factor-receptor 3 (FGFR3) Lys650 codon is located within a critical region of the tyrosine kinase-domain activation loop. Two missense mutations in this codon are known to result in strong constitutive activation of the FGFR3 tyrosine kinase and cause three different skeletal dysplasia syndromes-thanatophoric dysplasia type II (TD2) (A1948G [Lys650Glu]) and SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans) syndrome and thanatophoric dysplasia type I (TD1) (both due to A1949T [Lys650Met]). Other mutations within the FGFR3 tyrosine kinase domain (e.g., C1620A or C1620G [both resulting in Asn540Lys]) are known to cause hypochondroplasia, a relatively common but milder skeletal dysplasia. In 90 individuals with suspected clinical diagnoses of hypochondroplasia who do not have Asn540Lys mutations, we screened for mutations, in FGFR3 exon 15, that would disrupt a unique BbsI restriction site that includes the Lys650 codon. We report here the discovery of three novel mutations (G1950T and G1950C [both resulting in Lys650Asn] and A1948C [Lys650Gln]) occurring in six individuals from five families. Several physical and radiological features of these individuals were significantly milder than those in individuals with the Asn540Lys mutations. The Lys650Asn/Gln mutations result in constitutive activation of the FGFR3 tyrosine kinase but to a lesser degree than that observed with the Lys540Glu and Lys650Met mutations. These results demonstrate that different amino acid substitutions at the FGFR3 Lys650 codon can result in several different skeletal dysplasia phenotypes.

Citing Articles

Syndrome-informed phenotyping identifies a polygenic background for achondroplasia-like facial variation in the general population.

Vanneste M, Hoskens H, Goovaerts S, Matthews H, Devine J, Aponte J Nat Commun. 2024; 15(1):10458.

PMID: 39622794 PMC: 11612227. DOI: 10.1038/s41467-024-54839-1.


FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.

Noeraparast M, Krajina K, Pichler R, Niedersuss-Beke D, Shariat S, Grunwald V Cancer Commun (Lond). 2024; 44(10):1189-1208.

PMID: 39161208 PMC: 11483561. DOI: 10.1002/cac2.12602.


A case of long-term survival of SADDAN treated with growth hormone for marked short stature.

Kanno J, Katata Y, Kawashima S, Shima H, Sogi C, Umeki I Clin Pediatr Endocrinol. 2024; 33(3):144-150.

PMID: 38993719 PMC: 11234192. DOI: 10.1297/cpe.2023-0068.


Probing phosphorylation events in biological membranes: The transducer function.

Wirth D, Ozdemir E, Hristova K Biochim Biophys Acta Biomembr. 2024; 1866(7):184362.

PMID: 38885782 PMC: 11365757. DOI: 10.1016/j.bbamem.2024.184362.


Exploring FGFR3 Mutations in the Male Germline: Implications for Clonal Germline Expansions and Paternal Age-Related Dysplasias.

Moura S, Hartl I, Brumovska V, Calabrese P, Yasari A, Striedner Y Genome Biol Evol. 2024; 16(2).

PMID: 38411226 PMC: 10898338. DOI: 10.1093/gbe/evae015.


References
1.
Kitoh H, Brodie S, Kupke K, Lachman R, Wilcox W . Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia Type I. Mutations in brief no. 199. Online. Hum Mutat. 2000; 12(5):362-3. View

2.
Bellus G, Bamshad M, Przylepa K, Dorst J, Lee R, Hurko O . Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet. 1999; 85(1):53-65. View

3.
Winterpacht A, Hilbert K, Stelzer C, Schweikardt T, Decker H, Segerer H . A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics. 2000; 2(1):9-12. DOI: 10.1152/physiolgenomics.2000.2.1.9. View

4.
Grigelioniene G, Eklof O, Laurencikas E, Ollars B, Hertel N, Dumanski J . Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia. Acta Paediatr. 2000; 89(9):1072-6. DOI: 10.1080/713794579. View

5.
Beals R . Hypochondroplasia. A report of five kindreds. J Bone Joint Surg Am. 1969; 51(4):728-36. View